What is BellBrook Labs?
BellBrook Labs operates at the intersection of biotechnology and pharmaceutical research, specializing in the development of innovative assay solutions for enzyme drug targets. With a legacy spanning over two decades, the company provides a comprehensive suite of high-throughput screening (HTS) kits, active enzymes, and bespoke assay development services. Their client base, which includes major pharmaceutical entities, biotech innovators, and academic research institutions, relies on BellBrook for the robust data integrity required to advance therapeutic pipelines in complex areas such as oncology and autoimmune disorders. The firm's commitment to scientific rigor and technical expertise makes it an essential partner in the global drug discovery value chain.
How much funding has BellBrook Labs raised?
BellBrook Labs has raised a total of $137K across 1 funding round:
Debt
$137K
Debt (2021): $137K with participation from PPP
Key Investors in BellBrook Labs
PPP
Public-Private Partnership
What's next for BellBrook Labs?
With the successful closure of this late-stage funding round, BellBrook Labs is poised to scale its operational capacity and expand its product portfolio. The strategic allocation of this capital will likely focus on enhancing high-throughput screening capabilities and deepening the company's footprint in the competitive drug discovery market. As the industry shifts toward more precise enzyme-targeted therapies, BellBrook is strategically aligned to capitalize on the increasing demand for high-quality, reliable assay data. Future growth will likely be driven by continued investment in R&D and the expansion of their custom assay development services, ensuring they remain at the forefront of biochemical innovation.
See full BellBrook Labs company page
